SEC Form 4 · accession 0001209191-19-007776
VERTEX PHARMACEUTICALS INC / MA · VRTX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Amit Sachdev
Officer — EVP, CRO
Period of report
Feb 4, 2019
Accepted (ET)
Feb 6, 2019 · 4:51 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000875320
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Feb 4, 2019 | M | 1,942 | $86.52 | A | 48,604 | D | |
| Common StockF2,F3 | Feb 4, 2019 | S | 1,200 | $186.57 | D | 47,404 | D | |
| Common StockF3,F4 | Feb 4, 2019 | S | 742 | $187.35 | D | 46,662 | D | |
| Common Stock | Feb 4, 2019 | M | 2,155 | $91.05 | A | 48,817 | D | |
| Common StockF3,F5 | Feb 4, 2019 | S | 1,120 | $186.52 | D | 47,697 | D | |
| Common StockF3,F6 | Feb 4, 2019 | S | 1,035 | $187.23 | D | 46,662 | D | |
| Common StockF3,F7 | Feb 4, 2019 | S | 5,000 | $186.55 | D | 41,662 | D | |
| Common StockF3,F8 | Feb 4, 2019 | S | 3,625 | $187.30 | D | 38,037 | D | |
| Common Stock | holding | — | — | — | 12,215 | I | Held in Trust | |
| Common Stock | holding | — | — | — | 882 | I | 401(k) |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F9 | $86.52 | Feb 4, 2019 | M | 1,942 | D | — | Feb 2, 2027 | Common Stock | 1,942 | 15,533 | D |
| Stock Option (Right to Buy)F10 | $91.05 | Feb 4, 2019 | M | 2,155 | D | — | Feb 1, 2026 | Common Stock | 2,155 | 8,622 | D |
Explanation of responses
- F1Transaction made pursuant to Mr. Sachdev's company approved trading plan under Rule 10b5-1.
- F10The option vests in 16 quarterly installments from 2/2/2016.
- F2Open market sales reported on this line occurred at a weighted average price of $186.57 (range $185.99 to $186.90).
- F3Mr. Sachdev undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
- F4Open market sales reported on this line occurred at a weighted average price of $187.35 (range $187.03 to $187.59).
- F5Open market sales reported on this line occurred at a weighted average price of $186.52 (range $185.90 to $186.89).
- F6Open market sales reported on this line occurred at a weighted average price of $187.23 (range $186.94 to $187.60).
- F7Open market sales reported on this line occurred at a weighted average price of $186.55 (range $185.90 to $186.90).
- F8Open market sales reported on this line occurred at a weighted average price of $187.30 (range $186.92 to $187.63).
- F9The option vests in 16 quarterly installments from 2/3/2017.